Abstract: Purified genes encoding a T cell surface antigen from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding this antigen are provided. Methods of using said reagents and diagnostic kits are also provided.
Type:
Application
Filed:
November 14, 2014
Publication date:
March 5, 2015
Inventors:
DANIEL M. GORMAN, TROY D. RANDALL, ALBERT ZLOTNIK
Abstract: There is provided an epsilon toxin epitope polypeptide comprising a sequence of at least 10 contiguous amino acids from SEQ ID NO:3, the sequence comprising a mutation of at least one tyrosine residue compared to the equivalent sequence in SEQ ID NO:3, the polypeptide being capable of binding an antibody which binds to SEQ ID NO:5 and having reduced toxicity compared with the toxicity of SEQ ID NO:5. The polypeptide is useful in a method of vaccinating a subject against developing a disease caused by Clostridium perfringens and/or caused by (or associated with the presence of) active epsilon toxin.
Type:
Application
Filed:
March 28, 2013
Publication date:
March 5, 2015
Inventors:
Richard W. Titball, Monika Bokori-Brown, Claire Naylor
Abstract: The invention provides compositions and methods for laser actuated drug delivery. Compositions comprise serum albumin based particles conjugated with therapeutic agents which cab become bioavailable upon actuation of the particles by light, e.g. low power laser.
Abstract: The present invention relates to various soluble forms of CD31, including a novel form which is shed by activated platelets and released into the circulation. Methods for detecting said soluble forms of CD31 are disclosed, as are methods of specifically 1 detecting said platelet-derived shed CD31 and the use of such methods as a diagnostic tool.
Abstract: The present invention provides nucleic acids and peptides, and methods of using the nucleic acids and peptides to identify subjects at risk for a TDP-43 proteinopathy. The invention also provides for an array comprising the nucleic acids and peptides of the invention.
Type:
Application
Filed:
October 14, 2014
Publication date:
March 5, 2015
Inventors:
Nigel J. Cairns, Robert H. Baloh, Alan Pestronk, Michael A. Gitcho, Alison M. Goate
Abstract: Labelled polypeptide constituted by: (i) a peptide fragment of 38 to 50 amino acids including a peptide of sequence SEQ ID NO: 1, and (ii) a label selected from the group constituted by radioactive groups, non-protein fluorophors, protein fluorophors, magnetic particles or a paramagnetic spin label, in order that when the label is a fluorophor protein, the labelled polypeptide further contains a peptide spacer of 3 to 15 amino acids, located between the peptide fragment and the label and use thereof as a diagnostic tool.
Abstract: A method of preparing a reprogramming induced pluripotent stem cell from a human-derived somatic cell using a fusion protein in which a reprogramming inducing factor and cell permeable peptide (CPP) are fused, and a fusion protein in which a reprogramming inducing factor and a cell permeable peptide are fused are disclosed. According to the present invention, the induced pluripotent stem cell having high efficiency and high stability can be prepared by maximizing the effect of the reprogramming inducing transcription factor beyond the existing viral peptide transporter, in inducing the reprogramming of the somatic cell.
Type:
Application
Filed:
August 27, 2014
Publication date:
March 5, 2015
Inventors:
Yoon Jeong Park, Gene Lee, Hyun Nam, Jin Sook Suh, Chong-Pyoung Chung, Jue-Yeon Lee
Abstract: A process for recovering a proteinaceous material from a fermentable organic material, comprising: (i) forming an aqueous mixture of a fermentable organic material and a fermentation agent capable of fermenting the organic material to produce ethanol, wherein the organic material is a vegetable material containing protein; (ii) fermenting the aqueous mixture to produce ethanol; (iii) recovering from the fermented aqueous mixture an ethanol stream which is rich in ethanol and a co-product stream comprising unfermented organic material, fermentation agent and an aqueous solution of dissolved solids in water; (iv) subjecting the co-product stream to a first separation stage to recover a first stream rich in the unfermented organic material and a second stream rich in the fermentation agent suspended in the aqueous solution; and (v) subjecting the first stream to a protein recovery step in which at least part of the fibre in the unfermented organic material is separated from the unfermented organic material to pr
Abstract: A chimeric polyvalent recombinant protein for use as a vaccine and diagnostic for Lyme disease is provided. The chimeric protein comprises epitopes of the loop 5 region and/or the alpha helix 5 region of outer surface protein C (OspC) types. The OspC types may be associated with mammaliran Borrelia infections.
Type:
Application
Filed:
August 1, 2014
Publication date:
March 5, 2015
Applicant:
VIRGINIA COMMONWEALTH UNIVERSITY
Inventors:
Richard T. MARCONI, Christopher EARNHART
Abstract: Provided are methods for treating a pathological condition associated with unbalanced osteoclast differentiation by providing an AQP-9 modulator. The modulator can be an AQP-9 inhibitor or an AQP-9 inducer. Also provided are methods for modulating osteoclast differentiation, methods for treating pathological conditions associated with unbalanced osteoclast differentiation, as well as pharmaceutical composition including such modulators.
Abstract: Methods, kits and systems for determining whether a reaction occurs between a chimeric transmembrane receptor and an intracellular interaction partner thereof within a cell.
Type:
Application
Filed:
September 3, 2013
Publication date:
March 5, 2015
Inventors:
Philippe Bastiaens, Stephanie Reisewitz, Giuseppe Arrabito, Leif Dehmelt, Silke Gandor, Hendrik Schroeder, Christof M. Niemeyer
Abstract: The present invention provides for the use of soluble forms of CD83 and nucleic acids encoding them for the treatment of diseases caused by the dysfunction or undesired function of a cellular immune response involving dendritic cells, T cells and/or B cells. The invention moreover provides soluble CD83 molecules specifically suited for said purpose, antibodies against said specific soluble CD83 proteins and assay methods and kits comprising said antibodies.
Type:
Application
Filed:
June 17, 2014
Publication date:
March 5, 2015
Applicant:
ARGOS THERAPEUTICS, INC.
Inventors:
ALEXANDER STEINKASSERER, MATTHIAS LECHMANN, ELISABETH ZINSER
Abstract: The invention relates to truncated growth factors and variants thereof. The invention also relates to methods of making and using the truncated growth factors. The invention further relates to compositions including a protease and a growth factor comprising a bone morphogenic protein (BMP) or a variant thereof. The invention also relates to methods of using the composition.
Type:
Application
Filed:
September 2, 2012
Publication date:
March 5, 2015
Applicant:
LIFENET HEALTH
Inventors:
Xiaofei Qin, Silvia Chen, Jingsong Chen, James Clagett
Abstract: The present invention provides methods for differentiating a pediatric subject with pediatric septic shock from a healthy pediatric subject or one having sudden inflammatory response syndrome (SIRS). Also provided is a method of predicting pediatric septic shock mortality in a pediatric septic shock patient.
Type:
Grant
Filed:
January 22, 2014
Date of Patent:
March 3, 2015
Assignees:
UTI Limited Partnership, Children's Hospital Medical Center
Inventors:
Beata Mickiewicz, Hans J. Vogel, Hector R. Wong, Brent W. Winston
Abstract: A molecular construct comprises a donor label, an acceptor label, a linker peptide disposed between the donor and the acceptor, the linker having a cleavage site sequence, and a spacer between at least one of (a) the donor and the cleavage site sequence and (b) the acceptor and the cleavage site sequence. Preferably, the construct is selected from the group consisting of CFP-(SGLRSRA)-SNAP-25-(SNS)-YFP, and CFP-(SGLRSRA)-synaptobrevin-(SNS)-YFP. In preferred embodiments, the linker peptide is a substrate of a botulinum neurotoxin selected from the group consisting of synaptobrevin (VAMP), syntaxin and SNAP-25, or a fragment thereof that can be recognized and cleaved by the botulinum neurotoxin. Advantageously, the spacer increases the electronic coupling between the donor label and the acceptor label relative to a corresponding construct without the spacer.
Abstract: The present invention relates to an antibody-like protein based on the tenth fibronectin type III domain (10Fn3) that binds to serum albumin. The invention further relates to fusion molecules comprising a serum albumin-binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
Type:
Grant
Filed:
May 2, 2011
Date of Patent:
March 3, 2015
Assignee:
Bristol-Myers Squibb Company
Inventors:
Michael L. Gosselin, David Fabrizio, Joanna F. Swain, Tracy Mitchell, Ray Camphausen, Sharon T. Cload, Eric Furfine, Paul E. Morin, Ranjan Mukherjee, Simeon I. Taylor
Abstract: The invention provides a scaffold of extracellular matrix polymers with recombinant chimeric peptides tethered thereto. The invention also provides recombinant chimeric peptides of antimicrobial peptides and extracellular matrix binding domains. The invention also provides methods for treating chronic wounds using the scaffold and/or recombinant chimeric peptides.
Type:
Grant
Filed:
June 26, 2013
Date of Patent:
March 3, 2015
Assignee:
Worcester Polytechnic Institute
Inventors:
Marsha Rolle, Fioleda Prifti, Chris Malcuit, Terri Anne Camesano, Tanja Dominko, Denis Kole
Abstract: New thrombolytic protein molecules such as recombinant staphylokinase or streptokinase, urokinase, tissue plasminogen activator and the like, and suitable variants thereof, for targeting to brain tissue or any other tissue by either fusing to, or by synthesizing the candidate thrombolytic molecule(s) with a protein sequence comprising a strong amphipathic alpha helix containing protein transduction domain. Thrombolytic protein molecule(s) so engineered with the protein transduction domain is useful for enhanced uptake of such protein thrombolytic molecule(s) across the cell membranes and tissues including the blood brain barrier and find their use in the treatment of vascular thrombosis including cerebrovascular disorders caused by cerebral thrombosis or cerebral haemorrhage when used a as a therapeutic. The design and processes for cloning, expression, purification and protein transduction of such proteins across cell membranes.
Abstract: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.
Abstract: To provide a reagent for assaying anti-Treponema pallidum antibody which reagent contains a polypeptide antigen and which reagent provides high assay sensitivity and high specificity, and to provide an assay method employing the assay reagent. The reagent for assaying anti-Treponema pallidum antibody, for use in an assay of anti-Treponema pallidum antibody on the basis of antigen-antibody reaction is characterized in that the reagent contains, as an antigen, a recombinant polypeptide containing at least domain C and domain D of Treponema pallidum 47 kDa antigen but containing no domain A1 of the 47 kDa antigen.
Type:
Grant
Filed:
March 31, 2011
Date of Patent:
March 3, 2015
Assignees:
Sekisui Medical Co., Ltd., Japan-Lamb Inc.
Abstract: The present invention generally provides methods and compositions for eliciting an immune response against Neisseria spp. bacteria in a subject, particularly against a Neisseria meningitidis serogroup B strain.
Type:
Grant
Filed:
October 21, 2011
Date of Patent:
March 3, 2015
Assignee:
Children's Hospital & Research Center Oakland
Abstract: The present invention provides compositions, methods, and assays for treating an inflammatory and/or autoimmune disease, and/or transplanted tissue rejection using anti-?? TCR antibodies and antibody fragments. Anti-?? TCR antibodies are antibodies which bind to a ?? TCR. Anti-?? TCR antibodies produced by the hybridoma TOL101 MCB are also provided.
Type:
Grant
Filed:
July 19, 2013
Date of Patent:
March 3, 2015
Assignee:
Tolera Therapeutics, Inc.
Inventors:
Daniel R. Getts, James J. Herrmann, John J. Puisis, Frank J. Fokta
Abstract: The invention provides compositions and methods for brown fat induction and activity through modulation of Fndc5 activity and/or expression. Also provided are methods for preventing or treating metabolic disorders in a subject through modulation of Fndc5 activity and/or expression. Further provided are methods for identifying compounds that are capable of modulating Fndc5 activity and/or expression.
Abstract: Methods and systems for computationally designing self-assembling polypeptides are disclosed. A representation of a docked configuration of a symmetric protein architecture can be determined by a computing device configured to computationally symmetrically dock representations of protein building blocks within a representation of a symmetric protein architecture, where symmetrically docking a representation of a particular protein building block can include determining a configuration of the protein building blocks in three-dimensional space within the symmetric protein architecture configured to generate interfaces between building blocks suitable for computational protein interface design. The amino acid sequence of the docked protein building blocks can be computationally modified to specify protein-protein interfaces between the plurality of protein building blocks that are energetically favorable to drive self-assembly of a protein that includes the modified amino acid sequence.
Type:
Grant
Filed:
March 13, 2013
Date of Patent:
March 3, 2015
Assignee:
University of Washington Through its Center for Commercialization
Inventors:
David Baker, Neil King, William Sheffler, Todd Yeates
Abstract: Methods and compositions have been described that relate to a newly identified polypeptide family wherein each member has O-glycosidase activity and specified sequence characteristics. This family of enzymes can be used for example for cleaving O-linked glycans and for synthesis of neoglycopeptides or neoglycoproteins.
Abstract: Disclosed is a newly identified B7 family member, zB7H6, which functions as a counter-receptor for the NK cell triggering receptor, NKp30. Methods and compositions for modulating NKp30-mediated NK cell activity based on the interaction of zB7H6 with NKp30, as well as related screening methods, are also disclosed. Further disclosed are anti-zB7H6 antibodies as well as antibody-drug conjugates comprising an anti-zB7H6 antibody conjugated to a therapeutic agent, including methods for using such antibodies and antibody-drug conjugates to exert therapeutic effects against zB7H6-expressing cells.
Type:
Grant
Filed:
November 10, 2010
Date of Patent:
March 3, 2015
Assignee:
Zymogenetics, Inc.
Inventors:
Cameron S. Brandt, Jacob J. Kennedy, Wenfeng Xu, Eugene C. Yi, Brian A. Fox, Zeren Gao, Pallavur V. Sivakumar
Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects. In particular, the invention relates to methods and compositions selected to monitor cardiorenal syndrome using assays that detect NGAL, preferably together with assays that detect natriuretic peptides such as BNP. Such methods and compositions can provide early indications of a deterioration in cardiorenal syndrome status, including prognosis regarding mortality and worsening renal function.
Abstract: The present invention refers to the recombinant vaccine against canine visceral leishmaniasis containing the recombinant A2 protein and saponin, monophosphoryl lipid A, or aluminum hydroxide plus CpG as an adjuvant, allowing the distinction between vaccinated and infected animals through conventional ELISA or immunofluorescence tests that employ antigens of promastigote forms of Leishmania.
Type:
Grant
Filed:
May 27, 2014
Date of Patent:
March 3, 2015
Assignee:
Universidade Federal de Minas Gerais—UFMG
Inventors:
Ana Paula Salles Moura Fernandes, Christiane De Freitas Abrantes, Eduardo Antonio Ferraz Coelho, Ricardo Tostes Gazzinelli
Abstract: Disorders such as headaches can be treated by administration of a botulinum toxin to a patient suffering therefrom, such as a migraine headache. A combined a fixed site/fixed dose and an optional follow the pain variable dosage and injection site paradigm is disclosed for optimizing clinical effectiveness of botulinum toxin administration for patients suffering headache, particularly chronic migraine.
Type:
Grant
Filed:
April 16, 2013
Date of Patent:
March 3, 2015
Assignee:
Allergan, Inc.
Inventors:
Catherine C. Turkel, Sheena K. Aurora, Mitchell F. Brin
Abstract: A method for recycling metals is provided by using extracellular proteins excreted by a specific thermophilic bacteria strain, Tepidimonas fonticaldi sp. nov., in which the extracellular proteins show excellent metal-ion binding ability, being useful in recycling rare earth metal ions and precious metal ions from geothermal fluids, boiler solutions, industrial wastewater or hard water.
Type:
Grant
Filed:
December 30, 2013
Date of Patent:
March 3, 2015
Assignee:
Industrial Technology Research Institute
Abstract: The purpose of the present invention is to provide an FAD-conjugated glucose dehydrogenase that is hard to be inhibited by the inhibitors such as 1,10-phenanthroline. The present invention relates to a modified glucose dehydrogenase (GLD), comprising an amino acid sequence of a wild-type FAD-conjugated glucose dehydrogenase (GLD) represented by SEQ ID NO: 1 having a substitution of at least one amino acid residue selected from the group consisting of amino acid residues at positions 298, 338, 340, 341, 343, 352, 354, 424, 426, 431 and 432, wherein the modified GLD has a reduced susceptibility to an inhibitor, as compared with the wild-type GLD, especially to said modified GLD, which has 40% or more of a relative activity when determined in a system wherein the inhibitor coexists at a final concentration of 1 mM based on an enzymatic activity when determined in a system wherein the inhibitor does not coexist.
Abstract: [PROBLEMS] To identify mutations that can serve as indicators for predicting the effectiveness of drug treatments in cancers such as lung cancer; to provide a means for detecting said mutations; and to provide a means for identifying, based on said mutations, patients with cancer or subjects with a risk of cancer, in which drugs targeting genes having said mutations or proteins encoded by said genes show a therapeutic effect. [MEANS FOR SOLVING] A method for detecting a gene fusion serving as a responsible mutation (driver mutation) for cancer, the method comprising the step of detecting any one of an EZR-ERBB4 fusion polynucleotide, a KIAA1468-RET fusion polynucleotide, a TRIM24-a BRAF fusion polynucleotide, a CD74-NRG1 fusion polynucleotide, and an SLC3A2-NRG1 fusion polynucleotide, or a polypeptide encoded thereby, in an isolated sample from a subject with cancer.
Type:
Application
Filed:
August 20, 2014
Publication date:
February 26, 2015
Inventors:
Takashi Kohno, Koji Tsuta, Kazuki Yasuda
Abstract: Methods and compositions are disclosed to target tumor cells with embodiments of the LIGHT proteins linked fused or conjugated to a targeting agent. These compositions bind to both human and mouse receptors with affinity sufficient to conduct preclinical and clinical trials, and with increased affinity as compared to the wild type human LIGHT protein. The targeting of embodiments of LIGHT to tumor cells reduces tumor growth and reduces metastases.
Abstract: The present invention relates to a technology and method of priming of an immune response using invariant chain linked antigen, when these are used to prime a subsequent booster immunization using any suitable vacci.
Type:
Application
Filed:
September 10, 2014
Publication date:
February 26, 2015
Applicant:
University of Copenhagen
Inventors:
Peter Johannes Holst, Allen Randrup Thomsen, Jan Pravsgaard Christensen, Mirjana Grujic
Abstract: Streptococcus pneumoniae is a major health concern, especially in very young, elderly, or immunocompromised patients. The present disclosure provides, inter alia, certain highly effective vaccines and pharmaceutical compositions in Streptococcus pneumoniae that contain fusion proteins. The antigens may be used therapeutically or prophylactically.
Abstract: This present invention provides C-TAB.G5 and C-TAB.G5.1 isolated polypeptides comprising the receptor binding domains of C. difficile toxin A and toxin B as set forth in the amino acid sequences of SEQ ID NO: 2 and SEQ ID NO: 4. The C-TAB.G5 and C-TAB.G5.1 isolated polypeptides may be used to neutralize toxic effects of C. difficile toxin A and/or toxin B.
Type:
Application
Filed:
September 5, 2011
Publication date:
February 26, 2015
Applicants:
Intercell USA, Inc., Valneva Austria GmbH
Inventors:
Larry R. Ellingsworth, David Flyer, Jing-Hui Tian, Steven R. Fuhrmann, Stefanie Kluepfel-Stahl, Gregory M. Glenn, Kerstin Westritschnig
Abstract: The invention relates to a recovery and/or purification process of hydrophobins involving organic solvents and does not require separation techniques. In particular, the invention relates to a method for selective alcohol precipitation of hydrophobin II.
Abstract: Methods and compositions for preparing dry formulations of Glucose Binding Proteins (GBPs) are disclosed. The GBPs may be stored as a dry formulation without significant loss of activity. After reconstitution, the GBPs may be used to determine the glucose concentration of a sample.
Type:
Application
Filed:
March 28, 2013
Publication date:
February 26, 2015
Applicant:
Becton, Dickinson and Company
Inventors:
Matthew S. Ferriter, Javier Alarcon, Glenn P. Vonk, Melody M.H. Kuroda, Mark Foster Sistare, Brandi Marie Ford
Abstract: The present invention includes compositions and methods for the diagnosis and treatment of lung cancer with a recombinant tumor-associated antigen loaded antigen presenting cell that generates a cytotoxic T lymphocyte specific immune response to at least one of SP17, AKAP-4, or PTTG1 expressed by one or more lung cancer cells.
Abstract: The invention provides isolated polynucleotide molecules that comprise a DNA sequence encoding an infectious RNA sequence encoding a genetically-modified North American PRRS virus, wherein the polynucleotide molecule lacks at least one detectable antigenic epitope of North American PRRS virus. The invention also provides vaccines comprising genetically modified North American PRRS virus, RNA molecules, plasmids and viral vectors comprising the isolated polynucleotide molecules. Also provided are isolated polynucleotide molecules further comprising at least one nucleotide sequence that encodes a detectable heterologous antigenic epitope, and vaccines comprising North American PRRS virus, RNA molecules, plasmids and viral vectors comprising such isolated polynucleotide molecules.
Type:
Application
Filed:
November 4, 2014
Publication date:
February 26, 2015
Inventors:
Jay Gregory CALVERT, Michael G. SHEPPARD, Siao Kun W. WELCH, Raymond R. R. ROWLAND, Dal-Young KIM
Abstract: Vaccination methods to control PCV2 infection with different PCV2 subtypes are disclosed. Specifically, a PCV2 subtype b (PCV2b) ORF2 proteins or immunogenic compositions comprising a PCV2b ORF2 protein are used in a method for the treatment or prevention of an infection with PCV2 of a different subtype, the reduction, prevention or treatment of clinical signs caused by an infection with PCV2 of a different subtype, or the prevention or treatment of a disease caused by an infection with PCV2 of a different subtype.
Type:
Application
Filed:
August 20, 2014
Publication date:
February 26, 2015
Applicant:
BOEHRINGER INGELHEIM VETMEDICA, INC.
Inventors:
Gregory HAIWICK, Marc Allan EICHMEYER, Luis Alejandro HERNANDEZ, Wesley Scott JOHNSON, Christine Margaret MUEHLENTHALER, Eric Martin VAUGHN
Abstract: Recombinant papaya mosaic virus (PapMV) coat proteins comprising one or more antigenic peptides derived from an influenza virus antigen, such as from the M2e peptide, fused at a position within a predicted random coil within 13 amino acids of the N-terminus of the coat protein, uses thereof to prepare virus-like particles (VLPs), and uses of the VLPs in influenza vaccines.
Abstract: Engineered transcriptional activator-like effectors (TALEs) are versatile tools for genome manipulation with applications in research and clinical contexts. One current drawback of TALEs is their tendency to bind and cleave off-target sequence, which hampers their clinical application and renders applications requiring high-fidelity binding unfeasible. This disclosure provides engineered TALE domains and TALEs comprising such engineered domains, e.g., TALE nucleases (TALENs), TALE transcriptional activators, TALE transcriptional repressors, and TALE epigenetic modification enzymes, with improved specificity and methods for generating and using such TALEs.
Type:
Application
Filed:
June 30, 2014
Publication date:
February 26, 2015
Applicant:
President and Fellows of Harvard College
Inventors:
David R. Liu, John Paul Guilinger, Vikram Pattanayak
Abstract: The present invention relates antidotes to anticoagulants targeting factor Xa. The antidoes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.
Type:
Application
Filed:
July 21, 2014
Publication date:
February 26, 2015
Inventors:
GENMIN LU, DAVID R. PHILLIPS, PATRICK ANDRE, UMA SINHA
Abstract: Disclosed are yeast-based immunotherapeutic compositions, hepatitis B virus (HBV) antigens, and fusion proteins for the treatment and/or prevention of HBV infection and symptoms thereof, as well as methods of using the yeast-based immunotherapeutic compositions, HBV antigens, and fusion proteins for the prophylactic and/or therapeutic treatment of HBV and/or symptoms thereof.
Type:
Grant
Filed:
February 19, 2014
Date of Patent:
February 24, 2015
Assignee:
GlobeImmune, Inc.
Inventors:
David Apelian, Thomas H. King, Zhimin Guo, Claire Coeshott
Abstract: This invention relates to protein separation and purification methods for both alpha-1-antitrypsin (AAT, also known as alpha-1 proteinase inhibitor, API, and A.sub.1-PI) and Apolipoprotein A-I (ApoA-1) from, for example, a fraction of human blood plasma. In certain embodiments, the invention provides methods for separating AAT from ApoA-1 at the initial stage of purification, so that the same starting material can be used as a source for both proteins. The methods further pertain to providing compositions of AAT and of ApoA-1 suitable for pharmaceutical use and are suitable for large-scale purification.
Type:
Grant
Filed:
December 3, 2013
Date of Patent:
February 24, 2015
Assignee:
CSL Behring GmbH
Inventors:
Nathan Brinkman, Douglas Bigler, Reinhard Bolli, Vreni Foertsch
Abstract: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.
Abstract: The present disclosure provides methods of diagnosing a subject as having a pulmonary disease or disorder, e.g., an eosinophilic disease or disorder based on the determination of white blood cell ratios. The disclosure also provides white blood cell ratio-based methods of treating, prognosing, or monitoring a pulmonary disease or disorder, as well as methods of methods of predicting a dosage regimen, identifying a candidate therapeutic agent, identifying a patient as a candidate for a therapeutic agent, and methods of designing a personalized therapy.
Type:
Grant
Filed:
May 17, 2012
Date of Patent:
February 24, 2015
Assignee:
MedImmune, LLC
Inventors:
David L Gossage, Deepak B. Khatry, Gregory P. Geba, Nestor Molfino, Joseph M. Parker
Abstract: The present disclosure relates to CBH I chimera fusion polypeptides, nucleic acids encoding the polypeptides, and host cells for producing the polypeptides.